Search results

ANSTO signed a cooperation agreement with ITER to enable Australia to engage with and benefit from participation in the world’s largest engineering project to create fusion energy.

Evidence for existence of a highly exotic and elusive state of matter, known as a magnetic ‘spin nematic’ phase in a natural mineral called linarite.

Awards and prizes granted at the User Meeting 2020 for scientists.

Recently, a small delegation, including Yandruwandha Yawarrawarrka representatives from the remote outback settlement of Innamincka SA, travelled to ANSTO to deliver rare wooden Aboriginal archaeological artefacts for measurements to determine their age and origin.

Dr Richard Garrett featured on an ABC National program that highlighted how far we are from a future with nuclear fusion energy. Image: Jamison Daniel, Oak Ridge Leadership Computing Facility

Neutron scattering helps clarify the arrangement of magnetic vortices, skyrmions, in material

International collaboration uses Australian Synchrotron on pioneering malaria research.

ANSTO maintains national capabilities in radionuclide metrology, the measurement and detection of ionising radiation, radioanalytical chemistry and nuclear forensics to support industry, government and scientific users.

Staff from ANSTO’s High Reliability team, Prashant Maharaj, Tina Paneras, and Sam Sonter were honoured to present at the International Atomic Energy Agency’s (IAEA) Train-the-Trainers Regional Training Course for Radiation Protection Officers in Vienna, Austria on 16 to 20 January 2023.

Infastructure used on the Energy Materials Project.

Specifications and Instrument references.

Media statement from ANSTO.

Study reveals that properties of polycrystalline materials can be derived from microscopic single crystal samples

Planetary science is an emerging research theme in Australia, and research at ANSTO is embedded in the heart of this.

ANSTO is proud to announce that a license has been issued by the Therapeutic Goods Administration to produce Lutetium-177 (Lu-177) for use in clinical trials.